GO
Loading...

Biotechnology

More

  • Alexandria CEO: Real estate a long-term play     Monday, 13 Jan 2014 | 2:38 PM ET

    Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss its firm's success, and how rising yields impact its dividend.

  • Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss real estate demand in the biotech industry.

  • Perrigo CEO: Got to get our name out     Monday, 13 Jan 2014 | 2:24 PM ET

    Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.

  • Perrigo CEO: Elan purchase lowers tax rate     Monday, 13 Jan 2014 | 2:24 PM ET

    Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.

  • Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.

  • Monsanto wins high court challenge on seed patents Monday, 13 Jan 2014 | 2:06 PM ET
    A protester against Monsanto genetically modified food in New York's Bryant Park.

    The Supreme Court upheld Monsanto's biotech seed patents on Monday, dealing a blow to organic farmers and critics of the company.

  • The outlook for biotech is "wonderful," explains Sam Isaly, Orbimed Advisors managing partner.

  • Shares of Intercept Pharmaceuticals are up more than 560 percent this week alone. Akiva Felt, Oppenheimer senior analyst, shares his optimistic view for the company.

  • Jan 6- Thermo Fisher Scientific Inc said it would sell three of its businesses to General Electric Co's healthcare unit for $1.06 billion, fulfilling a requirement for European antitrust approval to buy Life Technologies Corp..

  • Singapore growth going to hold up: Pro     Wednesday, 1 Jan 2014 | 9:51 PM ET

    Daryl Liew, Head Of Portfolio Management of REYL Singapore advises investors to look past short-term volatilities in the country's economy after Q4 GDP data missed expectations

  • U.S. FDA warns against nipple test for breast cancer Thursday, 12 Dec 2013 | 3:23 PM ET

    The Food and Drug Administration, in a statement to healthcare professionals, said it is concerned that women will believe misleading claims about a nipple aspirate test and not get mammograms or other needed breast imaging tests or biopsies.

  • *Celgene to take 5 pct stake in OncoMed. *Celgene stock down 1.4 pct. Dec 3- Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs.

  • Biotech index hits an all-time high     Thursday, 21 Nov 2013 | 1:32 PM ET

    CNBC's Seema Mody reports the biotech index has hit an all-time high in the Nasdaq.

  • Nov 21- Activist investor Carl Icahn disclosed a 12.63 percent stake in medical device maker Hologic Inc, prompting the company to adopt a shareholder rights plan to protect itself from hostile takeovers. Shares of Hologic, which makes screening tests for cancer and other diseases, rose 3 percent in late morning trading.

  • *Genome doubling process occurs naturally in plants. *Company has recently raised $65 million investment. MOSHAV SARONA, Israel, Nov 15- An Israeli enterprise which aims to boost global crop yields without the aid of genetic modification will sow its first commercial seeds within three years, the company pioneering the technique has told Reuters.

  • JNJ to pay $2.2 billion in US probe: Feds Monday, 4 Nov 2013 | 1:53 PM ET

    Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.

  • Biotech stocks bounce up     Thursday, 10 Oct 2013 | 3:20 PM ET

    CNBC's Seema Mody reports on the biggest movers in the Nasdaq including social media stocks like Facebook up 5 percent.

  • Francois Nader, NPS Pharmaceuticals president & CEO, discusses its lead product Gattex for "short bowel syndrome," the potential for Netpara and the solid performance of its stock.

  • How to play the biotech boom     Monday, 7 Oct 2013 | 2:36 PM ET

    Biotech stocks are some of Nasdaq's best performing this year. Joel Sendek, Stifel Nicolaus, looks at names leading the biotech boom.

  • Shutdown not huge for biotech: Pro     Tuesday, 1 Oct 2013 | 5:40 PM ET

    How are biotech companies and the FDA impacted by the government shutdown? Yaron Werber of Citi Investment Research, offers insight.

Most Popular Video

Wednesday, 16 Apr 2014 | 11:56 AM ET

Art Cashin, UBS director of floor operations, explains what played into yesterday's market reversal and tells what sectors are back in favor today.

Wednesday, 16 Apr 2014 | 12:25 PM ET

CNBC's Steve Liesman provides insight into the highlights of Fed Chair Janet Yellen's comments at The Economic Club of New York.

Wednesday, 16 Apr 2014 | 12:15 PM ET

Josh Spencer, T. Rowe Price portfolio manager, encourages investors to get some guts and buy into growth stocks like Tesla and Amazon. He shares his opinions on some of the old tech names.